Update bundle #4

Gone are—for now—the golden days when I would publish a new post each week. So, for as long as my schedule is going to be this busy, I’ll have to be content with update bundles. I thought I’d let you know about a few news items and interesting things going on in anti-ageing community.

News from LEAF

On June 30 LEAF will host their first Journal Club event, with dr Oliver Medvedik. The topic will be the implications of epigenetic alterations on aging and as a primary aging process.

The recurring crowdfunding campaign to support LEAF has reached $1110, thus surpassing the first goal of $1000. The next one is $2000, and it’d be great if you could help us reach it, and advertise the campaign so that others may help too.

Another way you can help is by becoming a volunteer—there’s never a shortage of stuff to do in the world of anti-ageing research advocacy, and your talents may be precious. You can also join the community on discord to find out what’s going on and how you can help.

Keep an eye on LEAF, because new campaigns are to be expected fairly soon.

The state of the art

Rejuvenaction does a lot of rejuvenation advocacy, but doesn’t talk much about rejuvenation science. That is on my to-do list and is going to change; for the time being, here’s a brief update on a few research projects, categorised for simplicity the SENS way. None of these is exactly news, but they may give you an idea of where we are in terms of progress, in case you have been out of the loop.

LysoSENS

Clearing up the indigestible junk that accumulates in our lysosomes as we age is crucial in the fight against age-related diseases. The SENS approach to the problem of lysosomal dysfunction consists in upgrading our lysosomes with genes that allow them to produce enzymes that break down the previously unbreakable. A first example of this type of therapy moving towards the clinic is that of LysoCLEAR, an enzyme product in the pre-clinical trial stage specifically tailored to treat age-related macular degeneration (AMD) and its early onset version, juvenile macular degeneration. AMD is one of the leading causes of blindness among the elderly; if successful, LysoCLEAR would not only help old and young alike get back their sight, but it could also pave the way to similar treatments for lysosomal dysfunction in different tissues of the body. Indeed, while LysoCLEAR is targeted to treat the macula, its creator Kelsey Moody is optimistic that the method behind LysoCLEAR can be adapted to target different tissues.

This is not exactly full-scale LysoSENS yet—because we’re not talking of inserting new genes anywhere but rather of a treatment based on enzyme replacement therapy—but it’s an excellent step forward and it definitely is a maintenance-based approach which, at the end of the day, clears out unwanted junk. I suppose it can be seen as a ‘manual’ version of LysoSENS, since the necessary enzymes to clear up the macula aren’t produced directly by the body but are delivered by the drug itself.

Another project, a joint effort by SENS Research Foundation and the Buck Institute for Research on Aging, may help us get to the ‘automatic’ version of LysoSENS. The goal of the project is testing out an improvement on somatic gene therapy that uses CRISPR to control where specific genes are added to the genome. Further coverage can be found on FA! —which I always recommend as your primary source for anti-ageing science, together with LEAF. (See Jim’s comment below for a clarification.)

ApoptoSENS

Another cause of pathology in old age is the accumulation of senescent cells—cells that should die, but do not have the decency to do so. These felons have stopped replicating entirely, but don’t die. Instead, they stick around and secrete harmful chemicals. Their existence is a bit of a trade-off: They’re useful in small amounts (they play a role in wound healing and help preventing cancer), but once we hit old age they’ve built up to intolerable amounts, and far from being a solution, they become a problem. That’s why they’re one of the primary targets of ApoptoSENS.

In the past few years, senolytics—drugs capable of targeting and destroying senescent cells—have been often in the spotlight among the anti-ageing research community. Several biotech companies, such as Oisin, Unity, and CellAge, are working on different types of senolytics to get rid of excess senescent cells. The Life Extension Advocacy Foundation ran a rather successful crowdfunding campaign for CellAge last year, and Unity’s senolytics are supposed to enter clinical trials in 2018. Additionally, SENS Research Foundation and the Buck Institute for Research on Aging have recently joined forces on a research project focussed on the clearance of senescent cells in the immune system, led by renowned expert Professor Judy Campisi.

Methuselah Foundation’s new fund

Earlier this year (I told you I’m a slow poster) Methuselah Foundation launched the Methuselah Fund, aimed at providing financial help for promising scientific teams that would like to launch their own company focussed on rejuvenation biotechs. Professional investors’ interest is definitely welcome, and you can get in touch with sergio@methuselahfund.com if you’re interested; however, participants to the Methuselah 300 can complete their pledge by investing in the Methuselah Fund as well.

Upcoming MMTP Longevity Panel

MMTP will host a panel with dr. Alexandra Stolzing, dr. Aubrey de Grey, and other guests in early June—the exact date is to be confirmed. The panel will be livestreamed on Facebook and is offered as one of the rewards for donating to MMTP’s fundraiser on Lifespan.io in 2016. If you have any question to for Alexandra or Aubrey, or the other guests, be sure to submit it to info@majormouse.org.

Advancing Conversations with Aubrey de Grey

If you want an inexpensive, lightweight book that discusses the key points of the rejuvenation cause, either for your own reading or to recommend to others who aren’t willing to go through Ending Aging, I suggest you take a look to Douglas Lain’s Advancing Conversations: Aubrey de Grey—Advocate for an Indefinite Human Lifespan. It’s short, not sciencey and thus simple to read, and it answers quite a few questions that a newbie to the cause may have.

LEAF’s new website is up and running

I’m happy to announce that the Life Extension Advocacy Foundation, or LEAF, has launched their new website. Perhaps I should say ‘our new website’, as I have the privilege of being part of the team. Among the many resources available on the website, there’s a rich FAQ section, explaining the biology of ageing, the technologies we can use to defeat age-related diseases, and answers to objections to and concerns about rejuvenation. Check it out, and while you’re at it, have a look at our latest crowdfunding campaign for CellAge, currently 7% funded.

Crowdfunding against senescent cells on Lifespan.io

Today, Lifespan.io has launched a new crowdfunding campaign: CellAge: Targeting Senescent Cells With Synthetic Biology. As you may know, senescent cells are a major driver of a number of age-related diseases, and therefore a prime target for any respectable rejuvenation biotech platform. CellAge, a biotech company based in Edinburgh, aims to design synthetic promoters for safe and precise targeting of senescent cells, with the goal of developing senolytic gene therapies to remove them. Please, consider helping them with a donation—big or small, every dollar counts—and by spreading the word!

New fundraisers for SENS rejuvenation research

Hiya folks, just a quick note to let you know about two important things.

SENS 2016 winter fundraiser

Thanks to a generous grant from the Forever Healthy Foundation, every dollar donated to SENS until the end of this year will be doubled, up to the first 150.000$. (As a side note, FHF has already pledged 10$ million to SENS and SENS related research. These guys are awesome.)

FightAging!’s new fundraiser

In order to encourage regular donations to SENS, Reason of FA! and Josh Triplett have put together a matching fund of 24.000$ dollars; for a year starting on November 1st, 2016 they will match the donations of anyone signing up as a SENS patron.

fa-2016-fundraiser-2-600x400

Make a difference—help SENS bringing ageing under medical control!

Surprise! OncoSENS continues

The exciting announcement regarding the OncoSENS campaign I was talking about a few posts ago is that it got a 31-day extension, plus a matching fund of 15.000$. In other words, every dollar donated in the next 31 days will unlock an extra dollar from the fund, up to the first 15.000$. Right now the campaign is 58% funded, so there’s plenty of time to reach the goal and beyond. Pretty cool, eh? We’re counting on your help.

Short update

As I was saying elsewhere, the past month or so has been rather busy, and I haven’t had time to write a line anywhere. Now that that’s dealt with, let me give you a short update on what’s new with the rejuvenation world before I move on to some more meaty post.

You probably already know about Michael Greve’s lavish donation to ageing research, for which humanity as a whole should be grateful. That’s very good news. Still on the subject of money, the OncoSENS crowfunding campaign will end in about a day, and last time I checked it had reached around 56% of its 60.000$ goal. You still have time to make your contribution—they’re all welcome, big and small ones alike. I hear from Keith Comito of Lifespan.io that an “exciting announcement” about the campaign will be made during the RB2016 live streaming—because yes, they’re doing streaming it this year—and I’m looking forward to know what it is.

Cha-ching!

I’m a slow poster, you know that. Sometimes I’ve posted about ‘news’ that were a month old. That’s because life comes often in between.

However, this time around life can stuff it. I don’t want to be late for this news.

On July 12, 2016, SENS Research Foundation announced that Internet entrepreneur Michael Greve, who runs the Forever Healthy Foundation and KIZOO Technology Ventures, has committed a whopping 10.000.000$ (let me spell that for you: ten fucking million dollars) to SENS research and to startups focused on bringing rejuvenation therapies to the market.

In the words of Greve himself, “My goal is to provide support for the critical research of the SENS Research Foundation and to facilitate the development of the rejuvenation biotech industry and ecosystem. I think we should have more people contribute to the step-by-step creation of cures for the root causes of all age-related diseases. And we should have a whole rejuvenation industry based on the SENS treatment model including the self-accelerating feedback-loop of success stories and amazing opportunities for scientist [sic], entrepreneurs and VC investors. This will truly accelerate both research and therapies. I have decided to lead by example and make this $10 million commitment.”

Five of the 10 millions will be donated directly to SENS over the course of the next five years, while the other five, as said, will be donated to other startups of the field. The 5mln to SENS constitute 10% of the goal of SENS’s new initiative Project|21, meant to make the first human trials of rejuvenation biotechnologies happen by 2021.

That’s the kind of news that make my day. It’s the kind of news that makes you think rejuvenation biotechnologies just got a lot closer to being a reality.

However, don’t think that our job as rejuvenation supporters is over: We still need to keep spreading the word and donating what we can. Speaking of which, Lifespan.io’s OncoSENS campaign has been feeling terribly lonely as of late. It has reached a mere 19% of the goal, much less than other campaigns have reached in the same timespan. Why don’t you pay it a visit and bring in some friends?